- Home
- FULC vs ATLN Comparison
FULC vs ATLN Comparison
Compare FULC & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- ATLN
- Stock Information
- Founded
- FULC 2015
- ATLN 2014
- Country
- FULC United States
- ATLN United States
- Employees
- FULC N/A
- ATLN N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- ATLN
- Sector
- FULC Health Care
- ATLN
- Exchange
- FULC Nasdaq
- ATLN NYSE
- Market Cap
- FULC 210.9M
- ATLN 137.6M
- IPO Year
- FULC 2019
- ATLN 2021
- Fundamental
- Price
- FULC $2.90
- ATLN $6.00
- Analyst Decision
- FULC Hold
- ATLN
- Analyst Count
- FULC 8
- ATLN 0
- Target Price
- FULC $6.57
- ATLN N/A
- AVG Volume (30 Days)
- FULC 427.3K
- ATLN 63.8K
- Earning Date
- FULC 02-25-2025
- ATLN 01-01-0001
- Dividend Yield
- FULC N/A
- ATLN N/A
- EPS Growth
- FULC N/A
- ATLN N/A
- EPS
- FULC N/A
- ATLN N/A
- Revenue
- FULC $80,000,000.00
- ATLN $429,260,149.00
- Revenue This Year
- FULC N/A
- ATLN N/A
- Revenue Next Year
- FULC N/A
- ATLN N/A
- P/E Ratio
- FULC N/A
- ATLN N/A
- Revenue Growth
- FULC 2752.05
- ATLN 5.50
- 52 Week Low
- FULC $2.78
- ATLN $1.30
- 52 Week High
- FULC $11.85
- ATLN $8.98
- Technical
- Relative Strength Index (RSI)
- FULC 29.80
- ATLN N/A
- Support Level
- FULC $2.82
- ATLN N/A
- Resistance Level
- FULC $3.09
- ATLN N/A
- Average True Range (ATR)
- FULC 0.30
- ATLN 0.00
- MACD
- FULC -0.04
- ATLN 0.00
- Stochastic Oscillator
- FULC 10.86
- ATLN 0.00
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.